Based on the information available, Tigecycline, a broad-spectrum antibiotic, is indicated for the treatment of certain types of bacterial infections, including complicated skin and skin structure infections, complicated intra-abdominal infections, and community-acquired bacterial pneumonia [1]. However, the information does not specifically mention if Tigecycline can treat Methicillin-resistant Staphylococcus aureus (MRSA) infections.

According to the drug label from the FDA, Tigecycline has demonstrated in-vitro activity against some MRSA strains [2]. However, the label also states that the safety and efficacy of Tigecycline in treating MRSA infections have not been established in adequate and well-controlled clinical trials [2].

It is important to note that the development and spread of antibiotic-resistant bacteria, such as MRSA, is a significant concern in the medical community. The Centers for Disease Control and Prevention (CDC) estimates that MRSA causes more than 80,000 severe infections and 11,000 deaths in the United States each year [3].

In summary, while Tigecycline has demonstrated in-vitro activity against some MRSA strains, the safety and efficacy of Tigecycline in treating MRSA infections have not been established in clinical trials. It is crucial to consult with a healthcare provider for appropriate treatment options for MRSA infections.

Sources:

1. DrugPatentWatch.com. Tigecycline. <https://www.drugpatentwatch.com/drugs/tigecycline>.
2. FDA. Tigecycline Label. <https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021867s000lbl.pdf>.
3. CDC. MRSA. <https://www.cdc.gov/mrsa/community/index.html>.